Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Burnout shares some features with melancholic depression such as a feeling of loss of pleasure, energy. But it shares more similarities with non-melancholic depression such hopelessness, difficulty in ...

Want to protect yourself against diseases like dementia, stroke and depression? Reduce sedentary behavior and start ...

Magistrate Judge Joseph C. Spero of the U.S. District Court for the Northern District of California issued his opinion in Wit ...

Other income was $7.9 million for the fourth quarter of 2024, and $40.9 million for the year ended 2024, compared to $8.7 million and $31.4 million for the same periods in 2023. The increase in other ...

Severe mental illnesses and neuropsychiatric conditions in children, such as schizophrenia, bipolar disorder, major ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc.  pursuant and/or traceable to the registration statement and related prospectus ...

Handelsbanken Fonder AB lessened its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure ...

A recent study in Naturesuggests that getting Botox in the forehead might affect how the brain processes emotions. "The ...